KING OF PRUSSIA, PA.— Sept. 12, 2016 — Genomind, a personalized medicine company advancing mental healthcare through genetic testing, will present an educational webinar for clinicians interested in learning how the test can help guide personalized treatment for attention-deficit/hyperactivity disorder (ADHD) patients.
In the United States, approximately 11 percent of children 4–17 years of age (6.4 million) have been diagnosed with ADHD, according to the Centers for Disease Control and Prevention. Such diagnoses have a big impact on families, students and the nation’s healthcare system.
The results from Genomind’s Genecept Assay® allow clinicians to look for the most effective and tolerable dosages of treatments for ADHD. “This type of test is essential, because each person’s genetic code is unique. Several genes dictate how medication is processed in the body, how effective medicine may be, and whether the patient could be at risk for side effects,” says Dr. Mary Burns, an Atlanta psychiatrist.
Genomind’s on-demand educational webinar is available at: ADHD webinar; it educates clinicians on the genes tested, why they matter, and how the results can help clinicians in making treatment decisions. Participants also will learn about case studies. For instance, a 9-year-old boy had his medication changed by his clinician after taking the test; his teacher now notices significantly improved attention and ability to follow classroom instructions.
Research has found 87 percent of patients demonstrated a clinically measurable improvement with treatment guided by the Genecept Assay. It also reported improvement in 91 percent of patients who had previously failed at least two medications.
Genomind’s laboratory is a College of American Pathologists (CAP)-accredited facility; Genecept is approved in every state and the District of Columbia.
The Genecept Assay is available for use by any licensed and prescribing clinician. Patients should discuss with their clinician whether the Genecept Assay is right for them. Patients should have their clinician contact Genomind directly to order test kits and/or to receive more information about testing.
Genomind is a personalized medicine company bringing innovation to mental health care through genetic testing. Genomind is comprised of pioneering researchers and thought leaders in psychiatry and neurology and specializes in pharmacogenetic laboratory testing for psychiatry. Genomind is committed to partnering with clinicians to improve their patients’ lives. Learn more at www.genomind.com.
About the Genecept Assay®
The Genecept Assay® is a genetic test designed to help clinicians optimize treatment decisions for their patients with mental illness. It identifies patient-specific genetic markers that indicate which treatments are likely to work as intended, have no effect or cause adverse effects. It is an easily administered cheek swab test that analyzes key genes that have been selected based on hundreds of studies showing that variations in these genes can inform treatment decisions. The Assay is used to guide treatment for a range of psychiatric conditions, including depression, anxiety, obsessive-compulsive disorder (OCD), attention-deficit hyperactivity disorder (ADHD), bipolar disorder, post-traumatic stress disorder (PTSD), autism, schizophrenia, chronic pain and substance abuse, and has been shown in peer-reviewed published studies to improve patient outcomes and reduce overall medical costs. Each Assay provides clinicians with an easy-to-read patient report and a complimentary psychopharmacogenomic consultation. Learn more at www.genomind.com
Marketing Manager, Genomind